Abstract
Although efficacy of antipsychotic medications is well documented, their effectiveness in real-world practice is less robust. We examined the effectiveness of olanzapine and risperidone in schizophrenia in a naturalistic setting. We used an electronic medical records database at a Veterans Affairs Medical Center to conduct a retrospective study of all new outpatient medication trials of olanzapine (n = 221) and risperidone (n = 274) over a 2-year period beginning January 1999 in patients diagnosed with schizophrenia or schizoaffective disorder. We defined medication discontinuation as a switch between the 2 agents (most switches) or self-discontinuation when a patient is without medication supply for longer than 1 month. Sample mean age (+/-SD) was 48.4 (+/-11.6) years; 91% were men. Discontinuation rates were high (73%), trending lower in olanzapine (70%) than risperidone (76%) (P = 0.12). Median time to discontinuation was 120 days (95% confidence interval [CI], 105-135), longer for olanzapine (150 days; 95% CI, 120-180) than risperidone (90 days; 95% CI, 71-109) (P = 0.04). Self-discontinuation was high (48%), with no significant difference between olanzapine (50%) and risperidone (46%). Switching rate was 25% and more likel...Continue Reading
References
Oct 8, 1997·Journal of Clinical Psychopharmacology·P V TranG D Tollefson
May 1, 2001·The American Journal of Psychiatry·R R Conley, R Mahmoud
Mar 5, 2002·Psychiatric Services : a Journal of the American Psychiatric Association·Ramin MojtabaiEvelyn J Bromet
Aug 31, 2002·The American Journal of Psychiatry·Douglas L Leslie, Robert A Rosenheck
Sep 12, 2002·Schizophrenia Research·Delbert G RobinsonJeffrey A Lieberman
Nov 6, 2002·The Journal of Clinical Psychiatry·Jonathan P LacroDilip V Jeste
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Oct 14, 2003·Schizophrenia Bulletin·Michael J Sernyak, Robert Rosenheck
Jul 29, 2004·Schizophrenia Bulletin·Marcia ValensteinThomas Stavenger
Aug 10, 2005·The Journal of Clinical Psychiatry·Martin DossenbachSheila Assunção
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jul 11, 2006·BMJ : British Medical Journal·Jari TiihonenJari Haukka
Jan 2, 2007·The Journal of Clinical Psychiatry·Stefan Leucht, John M Kane
Sep 15, 2007·The Journal of Clinical Psychiatry·Eduardo DunayevichAlan I Green
Citations
Jun 11, 2011·Patient Preference and Adherence·Katarina KelinHaya Ascher-Svanum
Oct 4, 2014·International Journal of Mental Health Nursing·Anna Hegedüs, Bernd Kozel
May 18, 2011·Schizophrenia Research·Julie KreyenbuhlLisa B Dixon
Apr 5, 2012·Human Psychopharmacology·Susanne KraemerFréderic Rouillon
May 27, 2015·Human Psychopharmacology·Jennifer MillerDeanna L Kelly
Nov 26, 2010·Psychiatry Research·Erik G JönssonEva Lindström
Dec 16, 2016·Journal of Clinical Psychopharmacology·Hung-Yu ChanChiung-Hsu Chen
Dec 8, 2009·Journal of Psychopharmacology·Alvin Liew Siow Ann Chong
Dec 1, 2009·International Journal of Geriatric Psychiatry·C W RitchieD Ames
Nov 29, 2014·Pharmaceutical Biology·Maliheh SafaviAlireza Foroumadi
May 2, 2020·PeerJ·Wenjie GongEric D Caine
Oct 8, 2021·Translational Psychiatry·Lajos KatonaPál Czobor